Home » SCHERING BEGINS TRIALS OF ZK-EPO
SCHERING BEGINS TRIALS OF ZK-EPO
Schering has launched two Phase II trials in the U.S. and Canada to evaluate ZK-EPO, a pending breast and ovarian cancer treatment.
The breast cancer trial will be an open-label study at about 20 sites in the U.S. and Canada. Patients with metastatic breast cancer who failed on other chemotherapy options will receive ZK-EPO every three weeks.
In the second study, patients with recurrent ovarian cancer will be administered ZK-EPO in combination with carboplatin after first-line treatment with platinum-based chemotherapy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May